Along with an increasing aging population, the number of patients with OP and fragility fractures gradually increase. It is estimated that there will be 5.99 million patients with osteoporotic fractures by 2050 in China [10]. Recently, femoral neck fragility fractures have received more and more attention due to the high rate of morbidity and mortality [4].
DXA is currently the golden standard for the diagnosis of OP, but it is not sensitive to monitor early changes of BMD, the change of bone loss can be identified by DXA only when bone loss reaches a certain level [11]. Moreover, OP is characterized by insidious onset and slow progression and is easily to be ignored, several patients already missed the best opportunity for treatment before diagnosed, leading to a poor prognosis.
Femoral neck Lmax is defined as the maximum force that femoral neck can tolerate before fracture, and it is an important quantity for the mechanical property [12]. In our study, we founded that the femoral neck Lmax was significantly decreased with the decreasing of femoral neck BMD, indicating that femoral neck bone loss was linked to reduced femoral neck BMD. The reduced femoral neck BMD may be the trigger for the increased femoral neck bone fragility and osteoporotic fractures.
OPN is one of the main non-collagen proteins in bone tissue, it is mainly involved in inhibiting bone mineral deposition and accelerating bone loss [13]. Multiple studies have shown that OPN is significantly increased in patients with OP compared with patients with normal bone mass [14]. COL-I is the major components of organic bone matrix and has an important effect on bone mechanical strength. Haynl et al. [15] showed that the decline of COL-I protein expression can lead to an increase in the risk of OP. Although several studies have shown that OPN and COL-I both play an important role in the incidence and development of OP [16–18], there are few studies on the changes of OPN and COL-I protein expression in the femoral neck under different femoral neck BMD. The effects of OPN and COL-I on the bone loss and reduced bone strength of femoral neck are still unclear.
In our study, we showed that COL-I protein expression of femoral neck in the severe OP and OP groups was significantly lower than that in both normal group and osteopenia group (P < 0.05).
Furthermore, we found that protein expression of COL-I in femoral neck was positively correlated with the femoral neck Lmax (β = 0.149, P = 0.024), indicating that the reduced bone strength of femoral neck is related to COL-I protein expression, and the decreased expression of COL-I may be the cause of femoral neck OP and femoral neck fragility fractures. At the same time, we found that with the gradual decreases of femoral neck BMD and Lmax, expression of OPN gradually increased (P < 0.05). Furthermore, OPN was negatively correlated with the femoral neck BMD and Lmax (P < 0.05), indicating that the increased OPN might be the independent risk factor for the decline of femoral neck bone mass and bone strength. In addition, we are currently analyzing the interactions among the biochemical markers, spatial structure and biomechanical properties of femoral neck in order to fully elucidate the impact of the biochemical markers on the overall biomechanics of the femoral neck and their relationship with femoral neck fractures.
Serum BTMs can reflect the overall status of bone metabolism and detect the early changes of bone mass, they play an important role in guiding OP clinical diagnosis and treatment [19, 20]. However, there are multiple BTMs and which indicator can better reflect the early reduction of femoral neck bone mass and bone strength is still unknown. The results of our study showed that serum CTX, PINP, and OC levels in the severe OP and OP groups were significantly higher than those in the normal group (P = 0.000). These results are consistent with previous studies [21] showing that serum CTX, PINP and OC levels can reflect the changes in bone metabolism and bone mass, facilitating the early diagnosis and treatment of OP. We also found that serum CTX levels has changed significantly at the stage of femoral neck osteopenia, which indicates that serum CTX are more sensitive to the decline of femoral neck BMD, the measurement of serum CTX is conducive to early prevention and treatment of femoral neck OP. There are also some studies showing that with the decreases of BMD, serum OC levels gradually decrease [22]. Julien et al. [23] found that there was no significant difference in serum OC levels between OP patients and non-OP patients (P > 0.05). The discrepancy could be considered that all patients in previous studies were male who had relatively high peak bone mass, slow bone loss, and low conversion state of bone metabolism. Thus, the upward trend of serum OC levels in male patients is not significant.
After adjusting age, BMI and gender, multivariate linear regression analysis revealed that serum CTX was negatively correlated with femoral neck BMD and Lmax (P < 0.01), indicating that the increased serum CTX was the independent risk factor for the reduced, early measurement of CTX can better reflect the loss of femoral neck bone mass and bone strength. More than that, CTX could not only be used to monitor the early reduction of femoral neck bone mass and bone strength, and also be helpful to find patients with femoral neck osteopenia.
This study showed the cut-off value of serum BTMs for femoral neck osteopenia and OP. However, it is difficult to compare these results with previous studies because serum BTMs levels are dependent on the detection methods [24, 25]. Hu et al. [26] used electrochemiluminescence immunoassay to measure serum CTX levels and showed that the cut-off values of serum CTX, PINP, OC levels for diagnosing male OP were 0.38ng/mL, 42.43ng/mL, and 16.57ng/mL, respectively. The cut-off values for diagnosis of female OP were 0.21 ng/mL, 32.90 ng/mL, and 13.90 ng/mL, respectively. Therefore, different detection methods can lead to differences in the level of BTMs and the cut-off value for the diagnosis of osteopenia and OP needs to be further investigated. In addition, we found that the AUC of CTX and OPN for femoral neck osteopenia was significantly higher than that of PINP and OC, the AUC of OPN and COL-I for femoral neck OP was significantly higher than that of PINP and OC (P < 0.05), suggesting that CTX and OPN may have higher diagnostic value in femoral neck osteopenia, OPN and COL-I may have higher diagnostic value in femoral neck OP.
The results of the above studies confirmed that CTX, OPN and COL-I all can well reflect the early change of femoral neck bone mass and bone strength, and help to early identify patients at high risk for the femoral neck osteopenia and OP. However, we should extract the femoral neck bone tissue from patients in the clinical work, it would not only not only increase patient suffering but also limit clinical use because the detection process is tedious, subject to error and time-consuming, although OPN and COL-I both can directly reflect reduced femoral neck bone mass and bone strength. In our study, we found that CTX had the strongest relationship with femoral neck BMD and Lmax compared with OPN and COL-I, suggesting that CTX can better reflect the decline of femoral neck bone mass and bone strength. Furthermore, we found that CTX had significantly correlated with OPN and COL-I, indicating that CTX could be considered a surrogate marker for OPN and COL-I. We can be aware of the early change of femoral neck bone mass and bone strength from patients.
Despite the significance of our findings, our study still has some limitations that are worthy of mention. We plan to enlarge the sample size in the following study and standardize the examination process of each indicator to obtain more reliable achievements and to guide clinical practice more precisely in further.